FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/07/2026
Voltar para busca
Dado oficial do USPTO
CARSGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
09/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
09/04/2024
Data de registro
09/12/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/12/2025
Última transação
09/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
CN
Examinador
MAHMOUDI, MARIAM AZIZ
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
CARsgen Therapeutics Co., Ltd
Representantes
Adam Bell Bell IP Law
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; drugs for medical purposespharmaceutical preparations for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; biological preparations for medical purposes for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; medicinal solutions for injectionmedicines for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; biomedicine for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; blood for medical purposes; pre-filled syringes for medical purposes filled with pharmaceutical preparations for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; pharmaceuticals for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; biological tissue cultures for medical purposes; serotherapeutic medicines for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases
Classe 42
Scientific research; scientific laboratory services; research and development of new products for others; technical project studiesconducting scientific feasibility studies; technological research in the field of pharmaceutical studiesbiotechnologymedicineimmunotherapy; chemical research; chemistry serviceschemist services and chemistry consultation; chemical analysis; medical research; medical and scientific researchconducting clinical trials for others; biological research
Classe 44
Medical screening; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; human tissue bank services; alternative medicine services; therapy servicesmedical therapymedicine therapyimmunotherapycell therapygene therapyantibody therapyantibody-drug conjugate therapyradiation therapychemotherapystem cell therapy; telemedicine services; health care; medical clinic services
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
20/06/2026
FIMP
FINAL DISPOSITION PROCESSED
20/06/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/03/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/02/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/01/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
21/01/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/12/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
09/12/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/10/2025
PUBO
PUBLISHED FOR OPPOSITION
21/10/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/10/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/09/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
23/09/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
23/09/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
23/09/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
23/09/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/04/2025
GNFR
FINAL REFUSAL E-MAILED
04/04/2025
CNFR
FINAL REFUSAL WRITTEN
04/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/04/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/04/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/04/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/04/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/04/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/04/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/04/2025
RFNT
REFUSAL PROCESSED BY IB
17/11/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/10/2024
RFRR
REFUSAL PROCESSED BY MPU
29/10/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
23/10/2024
CNRT
NON-FINAL ACTION WRITTEN
22/10/2024
DOCK
ASSIGNED TO EXAMINER
22/10/2024
MAFR
APPLICATION FILING RECEIPT MAILED
23/08/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/08/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
22/08/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CARSGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.